Location History:
- Assam, IN (2014)
- Jorhat, IN (2015 - 2017)
Company Filing History:
Years Active: 2014-2017
Title: Nabin Chandra Barua: Pioneering Innovations in Cancer Treatment
Introduction
Nabin Chandra Barua, an esteemed inventor based in Jorhat, India, has made significant contributions to the field of pharmaceutical research, particularly in cancer treatment. With a total of three patents to his name, he continues to push the boundaries of medicinal science.
Latest Patents
One of Barua's latest inventions is a synergistic pharmaceutical composition useful for the treatment of lung cancer. This composition comprises Compound C2 (Neo-isopulegol), C3 (Iso-pulegol), and C4 (Citronellol), which are derived from herbal seed extracts. His research highlights the effectiveness of these compounds in killing A549 lung cancer cells, whether used alone or in combination.
Another noteworthy patent involves the development of 1,2,3-triazole containing artemisinin compounds and their preparation process. This patent describes the synthesis and bioassay results of artemisinin-derived compounds, which have shown activity against various cancer cell lines due to the unique 1,3-dipolar cycloaddition reaction of artemisinin-derived azide or alkyne with aliphatic or aromatic diazides.
Career Highlights
Nabin Chandra Barua is associated with the Council of Scientific & Industrial Research (CSIR), an organization known for its advanced scientific and industrial research. His innovative approach and dedication to improving healthcare through research are commendable.
Collaborations
Throughout his career, Barua has collaborated with notable scientists such as Paruchuri Gangadhar Rao and Partha Pratim Saikia. These partnerships have not only enriched his research but also accelerated advancements in cancer treatment methodologies.
Conclusion
Nabin Chandra Barua's work stands as a testament to the power of innovation in the fight against cancer. His contributions through his patents not only demonstrate his commitment to scientific advancement but also provide hope for improved therapeutic options for patients suffering from this devastating disease.